FOLH1 and neoplasm: In parallel, PSMA-targeting BiTEs are also under development (Chiu et al, 2020; Das et al, 2023; Leconet et al, 2018) and have shown anti-tumor activity in preclinical studies in mCRPC (Deegen et al, 2021).